Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Xeris Biopharma Holdings, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
09/29/2023 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION"
09/27/2023 8-K Quarterly results
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/08/2023 8-K Quarterly results
Docs: "XERIS BIOPHARMA REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS"
06/28/2023 8-K Regulation FD Disclosure  Interactive Data
06/07/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/09/2023 8-K Quarterly results
Docs: "XERIS BIOPHARMA REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS"
04/26/2023 ARS Form ARS - Annual Report to Security Holders:
04/26/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/26/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/29/2023 8-K Quarterly results
03/17/2023 8-K Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits  Interactive Data
03/08/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/08/2023 8-K Quarterly results
Docs: "XERIS BIOPHARMA REPORTS FOURTH QUARTER AND FULL-YEAR 2022 FINANCIAL RESULTS AND PROVIDES 2023 FINANCIAL GUIDANCE"
02/14/2023 SC 13G/A CAXTON CORP reports a 4.4% stake in Xeris Biopharma Holdings, Inc.
02/13/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/10/2023 SC 13G BlackRock Inc. reports a 6.3% stake in XERIX BIOPHARMA HOLDINGS INC
01/20/2023 8-K Entry into a Material Definitive Agreement  Interactive Data
01/05/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "XERIS BIOPHARMA UPDATES ITS OUTLOOK FOR 2022"
11/09/2022 8-K Quarterly results
Docs: "XERIS BIOPHARMA REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS AND RECENT EVENTS"
10/20/2022 8-K Quarterly results
10/03/2022 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
08/10/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/10/2022 8-K Quarterly results
Docs: "XERIS BIOPHARMA REPORTS SECOND QUARTER FINANCIAL RESULTS AND UPCOMING EVENTS"
06/08/2022 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/11/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
05/11/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/11/2022 8-K Quarterly results
05/02/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/28/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/28/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/11/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/11/2022 10-K Annual Report for the period ended December 31, 2021
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy